Short‐Term, Mid‐Term, and Long‐Term Outcomes of Transcatheter Aortic Valve Replacement With Balloon‐Expandable Versus Self‐Expanding Valves: A Meta‐Analysis of Randomized Controlled Trials

Le résumé fourni par la source

BACKGROUND: Comparisons of outcomes after transcatheter aortic valve replacement with balloon-expandable (BEV) versus self-expanding (SEV) valves are limited. HYPOTHESIS: This study aimed to compare clinical and hemodynamic outcomes of BEV and SEV at short-term (30 days), midterm (1 year), and long-term (> 1 year) endpoints. METHODS: PubMed, Embase, Scopus, and Cochrane Library databases were searched until July 2024 for randomized controlled trials. Random-effect model (DerSimonian-Laird method) was used to pool the risk ratios (RR), mean differences, and 95% confidence intervals (CI). RESULTS: A total of 10 studies comprising 4325 patients (2295 BEV, 2030 SEV) were included. In short-term, cardiovascular (RR: 0.56, 95% CI: 0.36-0.87) and all-cause mortality (RR: 0.54, 95% CI: 0.35-0.81) were lower in the BEV group. Risk of moderate to severe paravalvular leak (PVL) was lower among BEV patients in short-term (RR: 0.28, 95% CI: 0.17-0.49) and long-term (RR: 0.28, 95% CI: 0.1-0.79). A limited number of studies showed a greater risk of clinical valve thrombosis on BEV in midterm and long-term. The need for permanent pacemaker implantation was lower in BEV at both short-term (RR: 0.56, 95% CI: 0.37-0.87), and midterm (RR: 0.78, 95% CI: 0.64-0.94). The SEV group had a larger effective orifice area with lower mean transvalvular pressure gradient at all endpoints. CONCLUSIONS: BEV is associated with reduced risk of clinical outcomes in short-term; however, most differences diminish in longer evaluations, except for moderate to severe PVL, which remains elevated for SEV. SEVs had better hemodynamic results and lower risk of clinical valve thrombosis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.